The Standard

The Official Blog of Health Level Seven® International

visit HL7.org 

The Future of Clinical Trial Matching: Addressing Two Sides of the Same Coin – Perspectives from the CodeX and Vulcan HL7® FHIR® Accelerators – Part 2

[fa icon="calendar'] Apr 11, 2025 2:10:04 PM / by Vulcan and CodeX FHIR Accelerators posted in FHIR, interoperability, Connectathon, blue button, FHIR Accelerator, Vulcan, CodeX, mCODE, UDP, Common Protocol Template, Digital Data Flow

[fa icon="comment"] 0 Comments

Clinical Trial Matching...Room for Improvement 

Clinical trials are essential to the advancement of patient care. The outcomes of a trial directly enable the future development of new treatment options for patients. Participants also benefit during the trial – they are provided access to potential treatments that may not be otherwise available to them – sometimes improving their overall prognosis.

Trial sponsors (the party responsible for the clinical trial) make significant investments, including procurement of products and services supporting the clinical trial workflow. According to the Tufts Center for the Study of Drug Development (CSDD), the mean direct cost to conduct a clinical trial per day is approximately $40,000 for Phase II and Phase III trials, and delays to launching a product can cost $800,000 per day.

With a very high percentage of trials delayed due to enrollment, there is much work to do to ensure clinical trials are sustainable and new therapies reach patients faster. Efficiencies gained in clinical trial matching benefit patients and their caregivers, sponsors and service providers.

~

For a patient to be matched with the right trial, that patient’s medical history is compared with multiple trials’ criteria.   In concept, this is a simple process, but more information is often needed than is available in the patient’s record (in Part 1 we tell the story of Dr. Smith’s inability to easily obtain her patient’s medication history from his previous health care provider.) If, after a first evaluation, a patient isn’t disqualified, they must often undergo additional screening by their care team or more involved procedures required by the protocol sponsor to fully determine eligibility.

~

Read More [fa icon="long-arrow-right"]

Lists by Topic

see all

Posts by Topic

see all